ImaginAb is at the forefront of immuno-oncology, leveraging innovative technologies to enhance patient care through advanced imaging and radiopharmaceutical therapy. Their flagship technology, CD8 ImmunoPET, utilizes a unique 'minibody' antibody to provide comprehensive whole-body imaging of CD8 positive T-cells, which are crucial for the immune response against cancer. This imaging technique allows for real-time monitoring of a patient's immune status before, during, and after treatment, enabling healthcare providers to make informed decisions about the effectiveness of immunotherapies. By visualizing the distribution and activity of CD8 T-cells, ImaginAb's technology aims to improve clinical outcomes and accelerate the development of new cancer treatments.

In addition to CD8 ImmunoPET, ImaginAb is developing a range of radiopharmaceutical therapy (RPT) products that utilize their minibody and cys-diabody platforms to deliver targeted radiation to tumor cells. This approach is designed to enhance the precision of cancer treatments while minimizing damage to surrounding healthy tissues. The company is actively engaged in clinical trials across multiple continents, focusing on various indications, including prostate cancer and small-cell lung cancer. By integrating advanced imaging and targeted therapies, ImaginAb is committed to transforming the landscape of cancer treatment and improving the overall patient experience.

United States

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

ImaginAb

Company Details